ImmunoGen and Jazz collaborate to develop and market ADC products

ImmunoGen has entered a collaboration and option agreement to grant exclusive worldwide rights to Jazz Pharmaceuticals for the development and commercialisation of two haematology-related antibody-drug conjugate (ADC) candidates, IMGN779 and IMGN632.
Source: Pharmaceutical Technology - Category: Pharmaceuticals Source Type: news
More News: Grants | Pharmaceuticals